15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both NF1 and RET genes.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disease with an estimated incidence of 1 in 3000/3500 live births. NF1 is caused by a mutation in a gene which encodes a protein known as neurofibromin. In up to 5% of cases, NF1 is associated with pheochromocytomas. RET proto-oncogene encodes a member of the receptor tyrosine kinase family involved in the normal development or the neoplastic growth of neural crest cell lineages. Germ-line RET mutations account for cases of Multiple Endocrine Neoplasia type 2 (MEN2), an autosomal dominant genetic syndrome where medullary thyroid carcinoma (MTC) is the major and more clinically severe feature, with nearly complete penetrance. C-cell hyperplasia (CCH) is described in MEN2 patients, and it has been implicated as the precursor of in situ MTC. Patients with RET mutations develop pheochromocytomas in 50% of cases. Rarely, patients with NF1 have been found to present, in addition to the NF1 clinical picture, other lesions, such as parathyroid hyperplasia/adenoma and/or medullary thyroid carcinoma. In spite of the presence of these MEN2 lesions, in none of these patients mutations of gene RET have been found so far. In this report, we describe the first case of a patient affected by a germ-line mutation in both NF1 and RET genes.

          Related collections

          Author and article information

          Journal
          Gene
          Gene
          Elsevier BV
          1879-0038
          0378-1119
          Feb 25 2014
          : 536
          : 2
          Affiliations
          [1 ] Endocrinology Unit, Careggi Hospital, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. Electronic address: tonino.ercolino@unifi.it.
          [2 ] Department of Clinical and Experimental Medicine, University of Sassari, Azienda Ospedaliera Universitaria, Sassari, Italy.
          [3 ] Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
          [4 ] Medical Genetic Unit, IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
          [5 ] Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy; Istituto Toscano Tumori, Florence, Italy.
          Article
          S0378-1119(13)01649-1
          10.1016/j.gene.2013.12.003
          24361808
          24440b4d-896d-4484-bd5b-60ed24c1bde0
          History

          C-cells,CCH,CT,MEN2,MTC,Multiple Endocrine Neoplasia type 2,NF1,NF1 gene,Neurofibromatosis type 1,PKA,RET gene,Thyroid C-cell hyperplasia,calcitonin,medullary thyroid carcinoma,neurofibromatosis type 1,parafollicular cells,protein kinase A,C-cell hyperplasia

          Comments

          Comment on this article